Invesco
GALT icon

Invesco’s Galectin Therapeutics GALT Stock Holding History

Invesco’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
25,692
+1,899
+8% +$4.92K ﹤0.01% 3710
2026
Q1 		$66.4K Buy
23,793
+13,515
+131% +$41.1K ﹤0.01% 3668
2025
Q4 		$42.8K Buy
+10,278
New +$54.1K ﹤0.01% 3720
2021
Q2 		– Sell
-24,454
Closed -$53K – 3987
2021
Q1 		$53K Buy
24,454
+1,020
+4% +$2.29K ﹤0.01% 3825
2020
Q4 		$52K Buy
+23,434
New +$61.5K ﹤0.01% 3740
2018
Q4 		– Sell
-259,463
Closed -$1.56M – 3842
2018
Q3 		$1.56M Buy
+259,463
New +$1.43M ﹤0.01% 2926

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Invesco's GALT Position: Q2 2026 in Review

Invesco increased its Galectin Therapeutics (GALT) stake by 8% in Q2 2026, buying an estimated $4.92K and bringing the position to 25,692 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3710.

Invesco first reported a position in GALT in Q3 2018 and has held it in 6 quarters since. The position peaked at $1.56M in Q3 2018. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Invesco held 25,692 shares of Galectin Therapeutics worth $119K as of Q2 2026.
  • Invesco bought 1,899 Galectin Therapeutics shares in Q2 2026, an estimated $4.92K.
  • Galectin Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3710 holding.
  • Invesco first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 6 quarters since.
  • Invesco's Galectin Therapeutics position peaked at $1.56M in Q3 2018.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.